A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

Description

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments. The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819. Study details include: * The study duration will be up to 72 weeks * The treatment duration will be up to 52 weeks * A follow-up period of 20 weeks will be conducted * The number of on-site visits will be 7 and the number of phone contacts will be 5

Conditions

Chronic Obstructive Pulmonary Disease

Study Overview

Study Details

Study overview

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments. The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819. Study details include: * The study duration will be up to 72 weeks * The treatment duration will be up to 52 weeks * A follow-up period of 20 weeks will be conducted * The number of on-site visits will be 7 and the number of phone contacts will be 5

A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Participated in Either EFC16750 or EFC16819 Clinical Studies

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

Condition
Chronic Obstructive Pulmonary Disease
Intervention / Treatment

-

Contacts and Locations

Chandler

Chandler Clinical Research Trials- Site Number : 8401034, Chandler, Arizona, United States, 85286

Tucson

Noble Clinical Research Site Number : 8401182, Tucson, Arizona, United States, 85704

Lancaster

Antelope Valley Clinical Trials Site Number : 8401003, Lancaster, California, United States, 93534

Los Angeles

Downtown L.A. Research Center- Site Number : 8401027, Los Angeles, California, United States, 90017

Aurora

Allianz Research Institute CO Site Number : 8402061, Aurora, Colorado, United States, 80014

Boulder

Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8401180, Boulder, Colorado, United States, 80301

Boynton Beach

Helix Biomedics- Site Number : 8402049, Boynton Beach, Florida, United States, 33435

Cutler Bay

Beautiful Minds Clinical Research Center Site Number : 8401201, Cutler Bay, Florida, United States, 33157

DeBary

Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8402031, DeBary, Florida, United States, 32713

Hialeah

Direct Helpers Research Center- Site Number : 8402065, Hialeah, Florida, United States, 33012

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of a malignancy during parent study, except a squamous or basal cell carcinoma of the skin
  • * Any opportunistic infection during the parent study, such as tuberculosis (TB) or other infections whose nature or course may suggest an immunocompromised status
  • * Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment during the parent study
  • * Any situation that led to a permanent premature IMP discontinuation in parent trials

Ages Eligible for Study

40 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sanofi,

Clinical Sciences & Operations, STUDY_DIRECTOR, Sanofi

Study Record Dates

2026-12-01